Having started my career in the Indian Pharma industry as a Professional Service Representative to my last assignment as an Executive Vice President at Lupin, was an exciting journey of 30 years.

This was a journey of building performing teams in a large growing pharma company. We as a team built the NCD business from Rs 50 crores in 2003 to > Rs 1,500 crores in 2015. We built the business with value-integrated processes and developed a bench of leadership within the organization across the functions. From April 2015 onwards it’s been an interesting journey of Entrepreneurship with my core team focusing on acquisition opportunities and launching new business. We are very buoyant on the healthcare industry in India. India continues to remain a healthcare deficient country and therefore offers tremendous opportunity in various segments. The IPM with turnover of Rs.110,000 crores continues to show double digit growth. We estimate the IPM to double in the next five years. We plan to focus on high growth segments such as Dermatology, Cosmetology, Cardiology, Diabetes, Neurology, Pain management, Women’s healthcare and Nutraceuticals. Oaknet Healthcare will continue to explore opportunities both organic and inorganic to reach our goal of Rs 1,000 crore business in the next five years. Also collaboration and licensing will be an integral part of our business to build innovative solution to enhance patient care. I believe that next 5 to 7 years will be an exciting journey for all of us in creating a large size pharma company within short span of time. And the team will enjoy the benefit of growth.

– RS Raghav, MD CEO